Pasithea Therapeutics Corp. (KTTAW)

PriceLoading quote

Financial charts

Revenue

Net income

Free cash flow

Total cash / debt

CashTotal debt

Financial statements

5 annual periodsNewest to oldest
20252024202320222021
Revenue$486,559$15,062
Gross profit−$2,213
Research & development$8.0M$7.2M$8.1M$2.7M
Operating income−$20.9M−$14.2M−$16.0M−$12.6M−$4.5M
Net income−$20.4M−$13.9M−$16.0M−$13.9M−$2.2M
Basic EPSper diluted share-$2.91-$12.69-$0.42-$1.76-$0.21
Diluted EPSper diluted share-$2.91-$12.69-$0.42-$1.76-$0.21

Insider buys & sells

Jul 1, 2024Jun 30, 2026
Buys0$0.00 disclosed value
Sells (SEC code S)0$0.00 disclosed value
0 recent transactions
No insider transactions transactions were reported in the stored SEC coverage.